AmbioPharm, Inc.
AmbioPharm, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States, with significant operational regions across North America and Asia. Founded in 2004, the company has established itself as a trusted provider of high-quality peptide manufacturing and development services. AmbioPharm's core offerings include custom peptide synthesis, contract manufacturing, and research services, distinguished by their commitment to quality and innovation. With a focus on serving the biotechnology and pharmaceutical sectors, AmbioPharm has achieved notable milestones, including the expansion of its facilities to enhance production capabilities. The company is recognised for its competitive market position, driven by a dedication to customer satisfaction and a robust portfolio of unique products tailored to meet the evolving needs of its clients.
DitchCarbon Score
How does AmbioPharm, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AmbioPharm, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AmbioPharm, Inc.'s reported carbon emissions
AmbioPharm, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that AmbioPharm may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are encouraged to adopt measurable targets to reduce their environmental impact. As such, AmbioPharm may benefit from establishing clear emissions reduction goals and engaging in climate action initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AmbioPharm, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
